Bottom line
PJP vs PSCH: the short answer
PJP (Invesco Pharmaceuticals ETF) and PSCH (Invesco S&P SmallCap Health Care ETF) are quite different portfolios: only about 18% of their top holdings (by weight) are shared.
But PSCH is far broader, holding 81 positions to 33 for PJP, so beyond the top names it adds exposure PJP doesn't have.
PSCH is cheaper at 0.29% vs 0.58% — a difference of $29 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +0.6% for PSCH (reporting dates differ).
Updated Nov 19, 2026
PJP vs PSCH side by side
| PJP | PSCH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 0.29% |
| Annual cost per $10k | $58 | $29 |
| 10-yr cost on $10k (prospectus) | $726 | $368 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +27.9% | +3.8% |
| 5-yr return (annualized) | +9.0% | +0.6% |
| 10-yr return (annualized) | +5.1% | +8.4% |
| Best quarter | +18.1% | +28.4% |
| Worst quarter | −14.8% | −23.1% |
| Net assets (fund) | $472.1M | $131.4M |
| Number of holdings | 33 | 81 |
| Portfolio turnover | 36% | 42% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | PSCH | Difference |
|---|---|---|---|
| 2024 | +9.7% | +3.8% | +6.0% |
| 2023 | −2.2% | −2.6% | +0.4% |
| 2022 | −2.0% | −26.3% | +24.3% |
| 2021 | +14.5% | +5.6% | +8.9% |
| 2020 | +11.2% | +31.2% | −20.0% |
| 2019 | +4.7% | +19.9% | −15.2% |
| 2018 | −1.7% | +9.7% | −11.4% |
| 2017 | +15.3% | +34.4% | −19.1% |
| 2016 | −19.3% | +2.0% | −21.2% |
| 2015 | +11.1% | +20.3% | −9.2% |
Source: Fund prospectus bar charts
Holdings overlap
4 of PJP's top 25 holdings also appear in PSCH's top 25.
| Holding | PJP | PSCH |
|---|---|---|
| Invesco Private Prime Fund | 7.93% | 21.48% |
| Corcept Therapeutics Inc. | 4.96% | 3.47% |
| Invesco Private Government Fund | 3.73% | 8.27% |
| Ligand Pharmaceuticals Inc. | 3.20% | 2.43% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
PSCH top 10
- Invesco Private Prime Fund — 21.48%
- Invesco Private Government Fund — 8.27%
- Molina Healthcare, Inc. — 4.77%
- BrightSpring Health Services, Inc. — 4.35%
- Krystal Biotech, Inc. — 4.25%
- Alkermes PLC — 3.71%
- Corcept Therapeutics Inc. — 3.47%
- Glaukos Corp. — 3.17%
- PTC Therapeutics, Inc. — 3.16%
- Protagonist Therapeutics, Inc. — 3.12%
FAQ
What is the difference between PJP and PSCH?
Which is cheaper, PJP or PSCH?
Should I own both PJP and PSCH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.